Core Insights - The clinical-stage biopharmaceutical company has seen its shares increase by approximately 50% this year and over 70% in the last three months, with analysts projecting a potential upside of 164% based on an average price target of $23.71 per share [1][2]. Company Developments - The company announced promising clinical data for its lead candidate, palazestrant, which is an oral medication being evaluated for estrogen receptor-positive (ER+) breast cancer [2]. - Investors are optimistic about palazestrant ahead of a key clinical trial's primary readout expected in the second half of 2026, which could lead to FDA submission and commercialization [2]. Drug Mechanism and Comparison - Palazestrant is designed to completely shut off the estrogen receptor, potentially delaying tumor growth and maintaining disease stability for longer periods [4]. - The drug is part of the same therapeutic family as tamoxifen, but unlike tamoxifen, palazestrant does not have an agonist effect, meaning it does not trigger physiological responses elsewhere in the body [3]. - The company aims to improve targeting of the estrogen receptor, which is a validated molecular target in cancer, to provide better therapy for breast cancer patients, focusing on the approximately 70% of patients diagnosed with ER-positive or two-negative breast cancer [5].